Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

ProMetic to Commercially Launch Fibrinogen in the Fourth Quarter of 2014

Marketwired July 10, 2014

ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial

Marketwired June 18, 2014

ProMetic Receives a $5.6 Million Purchase Order from Octapharma

Marketwired June 5, 2014

ProMetic Reports its 2014 Annual and Special Meeting of Shareholders Highlights

Marketwired May 14, 2014

ProMetic Reports Its First Quarter 2014 Highlights and Financial Results

Marketwired May 14, 2014

ProMetic Increases Its Ownership Stake in NantPro BioSciences, LLC ("NantPro")

Marketwired May 9, 2014

ProMetic's PBI-4050 Delivers New Positive Preclinical Results in Liver Fibrosis and Liver Cancer

Marketwired April 10, 2014

ProMetic's PBI-4050 Delivers New Positive Preclinical Results in Liver Fibrosis and Liver Cancer

Marketwired April 10, 2014

ProMetic's PBI-4050 Shown to Reduce Blood Glucose and Kidney Fibrosis in Preclinical Models of Human Type II Diabetes and Kidney Disease

Marketwired April 3, 2014

ProMetic's PBI-4050 Shown to Reduce Blood Glucose and Kidney Fibrosis in Preclinical Models of Human Type II Diabetes and Kidney Disease

Marketwired April 3, 2014

ProMetic Reports Successful Pre-IND Meeting with the FDA

Marketwired April 2, 2014

ProMetic Reports Successful Pre-IND Meeting with the FDA

Marketwired April 2, 2014

ProMetic Reports its 2013 Fourth Quarter and Financial Year End Results and Business Highlights

Marketwired March 26, 2014

ProMetic Reports its 2013 Fourth Quarter and Financial Year End Results and Business Highlights

Marketwired March 26, 2014

ProMetic to Report its Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call/Webcast

Marketwired March 21, 2014

ProMetic Receives $3.2 Million Via Loan Repayment

Marketwired March 11, 2014

ProMetic Enters Into $1.6 Million Development Agreement With New Client

Marketwired February 6, 2014

ProMetic Announces the Appointment of its New Chief Medical Officer

Marketwired February 6, 2014

ProMetic Achieves Key Plasma Protein Manufacturing Milestone

Marketwired January 22, 2014

ProMetic Announces Operational Launch of its Plasma Purification Facility

Marketwired December 11, 2013